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ABSTRACT
Background: Tumour necrosis factor a blockers in
rheumatoid arthritis are known to increase the risk of
serious infections defined as life-threatening, requiring
hospitalisation or intravenous antibiotics. Recently, new
biological agents have become available. Their safety is an
important issue.
Purpose: To assess if biological agents, ie rituximab,
abatacept and anakinra increase the risk of serious
infections in patients with rheumatoid arthritis in
published randomised controlled trials.
Data source: A systematic review of the literature using
PUBMED, EMBASE, Cochrane library and abstracts
databases (American College of Rheumatology and
European League Against Rheumatism annual meetings)
was performed up to October 2007. This search was
completed with data from the Food and Drug
Administration, the European Agency for the Evaluation of
Medicinal Products and manufacturers.
Data extraction: Three fixed-effect meta-analyses were
performed to compare serious infection rates between
each biological agent and placebo. Pooled odds ratios
(ORs) were calculated, using the Mantel–Haenszel
method with a continuity correction.
Data synthesis: Twelve randomised controlled trials
with data concerning serious infections were analysed
(three for rituximab, five for abatacept and four for
anakinra). They included 745 patients, 1960 patients,
2062 patients and 2112 patients treated by rituximab,
abatacept, anakinra and placebo respectively. The overall
pooled ORs did not reveal a statistically significant
increased risk of serious infection for abatacept and
rituximab; this risk was increased for high doses of
anakinra (>100 mg daily) versus low dose and placebo
(ORs=9.63 (95% CI, 1.31 to 70.91) and 3.40 (95% CI,
1.11 to 10.46) respectively).
Conclusions: These meta-analyses did not reveal a
significant increase in the risk of serious infections during
rituximab or abatacept treatments in patients with
rheumatoid arthritis; however, high doses of anakinra may
increase this risk, especially when patients have
comorbidity factors. Large studies must be performed to
confirm this safety profile in daily practice.
Rheumatoid arthritis (RA) is a systemic autoim-
mune disorder characterised by chronic polyarti-
cular synovial inflammation that may lead to
irreversible joint damage with disability and
deformity. This joint inflammation is a result of
the excessive production by activated T cells of
pro-inflammatory cytokines, such as tumour
necrosis factor (TNF) a, interleukin (IL)-1, IL-6,
and the stimulation of immunoglobulin produc-
tion by B cells.
The conventional treatment of RA combines
corticosteroids and disease-modifying anti-rheu-
matic drugs (DMARDs), in particular, methotrex-
ate. However, RA may remain active despite such
treatments. Since 1997, new treatments based on
biological agents have demonstrated their efficacy
in RA. Biotherapies have different therapeutic
targets and some are aimed against pro-inflamma-
tory cytokines: three TNF-a blockers are available,
infliximab, etanercept and adalimumab
1–7 and one
IL-1 receptor antagonist, anakinra.
8 Down-regula-
tion of T cell activation is achieved by the
recombinant human fusion protein CTLA-4-
immunoglobulin G (abatacept)
9 and B cells are
the selective target of the chimeric anti-CD20
monoclonal antibody (rituximab).
10
Before the biotherapy era, it was reported that
the incidence rate of infections in the RA popula-
tion was nearly twice as high as in matched non-
RA controls.
11 This is thought to be related to the
disease itself, which alters immunological func-
tions, decreases mobility and causes skin defects,
and also to immunosuppressive drugs, in particular
concomitant use of steroids.
11 12 In post-marketing
surveillance and observational studies of TNF-a
blockers, serious infections (defined as life-threa-
tening or requiring intravenous antibiotics or
hospitalisation) appear to be the most frequent
adverse event with a prevalence of 6–18% and an
incidence rate of approximately 6 per 100 patient-
years.
13–15 Furthermore, case–control studies, con-
ducted in routine daily practice, showed that the
risk of serious infections was two- to three-fold
higher in patients receiving TNF-a blockers com-
pared with those not treated with such treat-
ment.
13–16 Thus it is clear that TNF-a blockers can
increase immunosuppression in patients with RA
and induce the emergence of serious infections.
Meta-analysis is an interesting method to detect
such a risk of a relatively rare event: a recent meta-
analysis of randomised placebo-controlled trials of
monoclonal anti-TNF-a antibodies (infliximab,
adalimumab) found a pooled odds ratio (OR) for
serious infections of 2.0 (95% confidence interval
(CI), 1.3 to 3.1) in TNF-a blocker treated patients.
17
However, individually, the trials had failed to
demonstrate this increased risk of serious infections.
For other biological agents that may interfere
with the immune response (rituximab, anakinra,
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of this study was to assess if these biotherapies increased the
risk of serious infections in patients with RA, by performing a
meta-analysis of data published to date.
METHODS
For each biological agent, a meta-analysis was conducted
according to the Cochrane Collaboration guidelines.
18
Study selection
A systematic literature search of the literature published up to
December 2007 was performed in PUBMED, EMBASE and
Cochrane library databases; without limitation of years of
publication or journal, using the followings key-words: ‘‘rheu-
matoid arthritis’’, ‘‘abatacept’’, ‘‘rituximab’’, ‘‘anakinra’’, ‘‘clin-
ical controlled trials’’, ‘‘clinical trials’’, ‘‘randomised controlled
trials’’, ‘‘clinical trials phase II, III, IV’’. We also included
congress abstracts of American College of Rheumatology (ACR)
and European League Against Rheumatism (EULAR) meetings
from 2004 to 2006, because we assumed that any abstract
published prior to 2004 had been published in a formal full-
length work. Moreover, to complete our search with unpub-
lished data, the Food and Drug Administration (FDA), the
European Agency for the Evaluation of Medicinal Products
(EMEA) and the manufacturers (Roche, Amgen and Bristol-
Myers Squibb) were contacted.
The trials were initially selected on the basis of their titles and
abstract. The inclusion criteria were randomised placebo-
controlled trials in adult patients with RA according to ACR
criteria.
19 The publications had to be written in English, French
or Spanish. The patients had to be randomised to receive
placebo or one of the three biological agents (rituximab,
anakinra and abatacept), as monotherapy or with concomitant
biological or non-biological DMARDs. Reviews and articles
reporting trials that were not placebo-controlled were excluded.
Data collection
One investigator (CS) selected the articles and collected the
data, using a predetermined form. The following methodologi-
cal features were collected: simple or double blinding, intention-
to-treat-analysis or not, number of participants who completed
the follow-up. For each trial, demographic characteristics
(percentage female, mean age), RA features and its duration,
treatment allocation (with doses and duration), concomitant
treatments (DMARDs, corticosteroids, non-steroid anti-inflam-
matory drugs) and duration of follow-up were collected. In the
literature, a serious infection is usually defined as life-threaten-
ing, requiring intravenous antibiotics or hospitalisations.
156
This definition was also used here; if another definition of
serious infections was given in the trials, it was also recorded.
The number of patients with at least one serious infection in
placebo and biological agent groups were collected. When
available, the characteristics of infections (localisation, organism
and outcome) were noted.
Statistical analysis
For each biological agent, a fixed-effects meta-analysis of
dichotomous outcomes was performed. This model has a
superior performance to random-effect models when pooling
trials with few or no events, such as serious infections.
20 Because
serious infections were rare events and some trials were small,
the Mantel–Haenszel method was chosen with a continuity
correction when there was no serious infection observed in one
study arm of a trial. The Mantel–Haenszel method was used to
estimate the pooled OR, with 95% CI, of all trials, assuming a
fixed-effect model. The CIs for ORs were evaluated using the
Robins, Breslow and Greenland variance formula and a x
2 test
was given with its associated probability that pooled ORs were
equal to 1. These statistical methods applied to each biological
agent and for all trials whatever the dose, and for two a priori
empirically pre-defined dose groups: low-dose group (500 mg for
rituximab, (2 mg/kg for abatacept and ,100 mg for anakinra)
and high-dose group (1000 mg for rituximab, 10 mg/kg for
abatacept and >100 mg for anakinra). We also performed a
sensitivity analysis concerning potential confounding factors of
infections. According to Doran et al
21 predictive factors of
serious infections in patients with RA were increasing age,
presence of rheumatoid factor (RF), extra-articular manifesta-
tions, nodules, increased erythrocyte sedimentation rate,
comorbidities (such as diabetes mellitus, chronic lung disease,
alcoholism, organic brain disease, leucopenia) and concomitant
steroid treatment. When available, these factors were included
in the sensitivity analysis. According to this study, duration of
RA, previous and concomitant DMARDs, sex, obesity and
smoking status did not appear as predictors of serious infections
in patients with RA. We used StatsDirect version 2.5.7
(StatsDirect Ltd, Cheshire, UK) and RevMan version 4.2
(Review Manager, Copenhagen, The Nordic Cochrane Centre,
2003) statistical software.
RESULTS
Literature search results and trials characteristics
Figure 1 shows the selection process of published trials for this
systematic review. Initially, 490 potentially relevant articles
were screened. Among them 477 were excluded. Finally, 13
randomised double-blind placebo-controlled trials were
included.
8–10 22–31 The characteristics of these trials are sum-
marised in table 1. Twelve published trials were selected for the
meta-analysis. One article was excluded from the meta-analysis
because it reported a trial already selected, with a different
follow-up:
24 25 for the meta-analysis, we selected the longest
follow-up (48 vs 24 weeks). No additional randomised con-
trolled trial was available from FDA, EMEA, manufacturers or
congress abstracts.
All of these 12 articles were randomised double-blind placebo-
controlled trials with a follow-up of 12–48 weeks, for patients
with RA according to the ACR criteria and with active disease
despite DMARDs. However, three studies concerned patients
with RA refractory to TNF-a blocker treatment.
92 22 6 In all
trials, an intention-to-treat analysis was performed and 94% of
the patients included completed the follow-up. Intention-to-
treat analysis included all randomised patients who received at
least one dose of study medication (modified intention-to-treat
analysis). Thus a total of 4767 patients received at least one dose
of one of the three biological agents and 2112 placebo. Eighty-
one per cent of the participants were women with a mean age at
inclusion of between 46 and 57 years. The mean duration of RA
was 9.2 years (range 3.4–12.1).
Serious infections
According to these trials, serious infection was defined as life-
threatening, fatal, requiring a hospitalisation, intravenous
antibiotics, or resulting in persistent or significant disability.
Tables 2 and 3 summarise the serious infections reported in the
12 trials, according to treatment groups with incidence and
ORs.
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Three trials fulfilled the criteria for analysis
10 22 23 (table 1).
Overall, 745 randomised patients with RA received at least one
dose of rituximab (500 mg or 1000 mg) and 398 received at least
one dose of placebo. The mean age of patients receiving
rituximab was 52.0 years. Among them, 490 had steroids as
concomitant treatment (65.7%) and 331 (among 624 patients
tested) were RF positive (82.5%). For patients allocated to
placebo, the mean age was 52.3 years, 253 had steroid treatment
(63.5%) and 207 (among 358 patients tested) were RF positive
(83.6%). Six and 17 serious infections were observed in the
placebo and rituximab groups respectively. These 17 serious
infections occurred in patients receiving 261000 mg infusions of
rituximab. No serious infections were observed in those treated
with the dose of 500 mg (table 2). The incidence of serious
infections was 2.3% and 1.5% in the rituximab and placebo
groups respectively (table 3). Using the Mantel–Haenszel
method, the overall pooled OR for serious infections whatever
the dose and according to the dose groups were not significantly
increased (tables 3 and 4, fig 2). In patients receiving rituximab,
serious infections were mainly respiratory tract bacterial infection.
Among the 17 patients who had one serious infection: five had
bronchopneumonia (one of them presented with two episodes of
Pseudomonas aeruginosa pneumonia), two septic arthritis (of whom
one Staphylococcus aureus septicaemia), three pyelonephritis and
two gastroenteritis and one each epiglottitis, cellulitis of a toe and
acute hepatitis B. One fatal bronchopneumonia occurred in a
patient receiving rituximab.
10 No opportunistic infection or
tuberculosis occurred in patients receiving rituximab.
Serious infections during abatacept treatment
Five published placebo-controlled trials fulfilled the selection
criteria for analysis
9 25–28 (table 1). A total of 2945 randomised
patients received at least one dose of abatacept (0.5, 2 or 10 mg/
kg) (n=1960) or placebo (n=985) for a duration of treatment
comprised between 24 and 48 weeks. One hundred and three
participants treated with abatacept and 64 patients receiving
placebo had TNF-a b l o c k e ro ra n a k i n r aa sc o n c o m i t a n tt r e a t -
ment.
28Intheabataceptgroups,themeanagewas49.6 years,1328
patients received steroids as concomitant treatment (67.7%) and
82.5% (among the 872 patients tested) were RF positive.
Concerning placebo groups, the mean age was 48.6 years, 655
patients took concomitant steroid treatment (66.5%) and 79.8%
(among the 471 patients tested) were RF positive.
In the abatacept group, 49 serious infections were observed
versus 18 in the placebo group (tables 2 and 3). Seven serious
infections (six in abatacept and one in placebo groups) occurred
in patients who received TNF-a blocker or anakinra as
concomitant treatment.
28 Thus, the incidence was 2.5% and
1.7% respectively with an overall pooled OR whatever the dose
and according to the dose groups not significantly increased
(tables 3 and 4, fig 2). The 49 serious infections occurring with
abatacept were mainly bronchopulmonary,
23 streptococcal and
pyogenic septicaemia,
2 staphylococcal arthritis,
2 abscesses,
2
gastrointestinal (six of whom three diverticulitis), dermatologi-
cal infections (six of whom one was a cellulitis) and pyelone-
phritis.
7 One case of unconfirmed tuberculosis and one case of
pulmonary aspergillosis were reported. The last patient (who
had a history of tuberculosis and pulmonary fibrosis) died of
aspergillosis and of a Pseudomonas aeruginosa septicaemia.
Serious infections during anakinra treatment
Four trials were included in the meta-analysis.
8 29–31 Their
characteristics are summarised in table 1. The meta-analysis
was performed on 2771 patients, randomised to receive at least
one dose of anakinra (n=2062) (0.04, 0.01, 0.4, 1, 2 mg/kg, 30,
75, 100 or 150 mg) or placebo (n=729), during 24 weeks.
Among these participants, 755 and 196 patients (who received
anakinra and placebo respectively) had comorbidity factors such
as pulmonary chronic disease, diabetes, renal impairment,
previous malignancy or infection, cardiovascular or central
nervous system diseases.
31 The proportion of patients with
comorbidity factors was similar in the anakinra and placebo
groups (67.6% and 69.2% respectively). In the anakinra groups,
the mean age was 54.2 years and 53.0%% received steroids as
concomitant treatment. Concerning placebo groups, the mean
age was 55.3 years and 55.0% received steroids. The prevalence
of RF was 74.6% in the anakinra groups and 75.1% in placebo
groups (for 946 and 446 patients tested respectively). Thirty
serious infections (1.4%) were observed in the anakinra group
versus 4 (0.5%) in placebo group (tables 2 and 3). Nineteen
serious infections (2.5%) occurred in patients with comorbidity
factors and treated with anakinra.
31 The overall pooled OR of
serious infections did not show a significantly increased risk of
serious infection. However, the risk was increased for a high
dose of anakinra versus low dose and high dose versus placebo
(ORs=9.63 (95% CI: 1.31 to 70.91) and 3.40 (95% CI: 1.11 to
10.46) respectively) (tables 3 and 4, fig 2). When patients with
comorbidity factors were excluded, these results were not
statistically significant whatever the dose groups (table 4).
Among the 30 serious infections occurring in anakinra-treated
groups, 11 were pneumonia. The others were osteomyelitis,
2
cellulitis,
3 bursitis, herpes zoster, infected bunion and gangrene
(one of each). No related death or opportunistic infections were
described.
Sensitivity analyses
Analyses of subgroups according to age (, or . to median,
52.7 years), concomitant intake of steroids (median 65% of
Figure 1 Systematic literature search selection process.
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confirmed the previous results (data not shown). Thus these
potential predictive factors of serious infections did not appear
as confounding factors.
DISCUSSION
These meta-analyses of published data did not evidence an
increased risk of serious infections for patients with RA treated
by rituximab or abatacept. However, results indicated a
significantly increased risk of serious infections for the high
dose of anakinra.
The meta-analyses of randomised placebo-controlled trials
that evaluated separately these three biotherapies included 12
trials: three for rituximab (745 patients treated), five for
abatacept (1960 patients) and four for anakinra (2062 patients).
Separately, these trials did not show an increased risk of serious
infections except for one concerning patients with comorbid-
ities receiving anakinra.
31 The calculated pooled ORs, whatever
the doses, did not show a significantly increased risk of serious
infections in patients treated with these three biological agents.
Indeed, overall ORs were 1.45 (95% CI, 0.56 to 3.73), 1.35 (95%
CI, 0.78 to 2.32) and 2.75 (95% CI, 0.90 to 8.35) for rituximab,
Table 1 Characteristics of the 12 randomised controlled trials of biotherapies in RA included in these meta-analyses for serious infections
Sources
(reference)
No. of randomised
patients (no. of
patients treated*)
No. who
completed the
follow-up RA characteristics
Study protocol with doses (no. of patients treated*
in each group)
Duration of
follow-up (weeks)
Rituximab
Edwards et al,
2004
10
161 (161) 130 Active RA despite MTX >10 mg per week of MTX+placebo (40)
1000 mg on days 1 and 15 of rituximab (40)
1000 mg on days 1 and 15 of rituximab+750 mg
on days 3 and 17 of cyclophosphamide (41)
1000 mg on days 1 and 15 of rituximab+
>10 mg per week of MTX (40)
48
Emery et al,
2006
22
465 (465) 375 Active RA resistant to
DMARDs, including
biological agents
10–25 mg per week of MTX+placebo (149)
1000 mg on days 1 and 15 of rituximab+
10–25 mg per week of MTX (192)
500 mg on days 1 and 15 of rituximab+
10–25 mg per week of MTX (124)
24
Cohen et al,
2006
23
520 (517) 366 Active RA despite TNF-a
blockers
10–25 mg per week of MTX+placebo (209)
10–25 mg per week of MTX+1000 mg on
days 1 and 15 of rituximab (308)
24
Abatacept
Moreland et al,
2002
9
122 (122) 90 Refractory RA despite
DMARDs or etanercept
Placebo (32)
0.5 mg/kg of abatacept on days 1, 15, 29 and 57 (26)
2 mg/kg of abatacept on days 1, 15, 29 and 57 (32)
10 mg/kg of abatacept on days 1, 15, 29 and 57 (32)
12
Kremer et al,
2003 and 2005
24 25
339 (339) 235 Active RA despite MTX 10–30 mg per week of MTX+placebo (119)
10–30 mg per week of MTX+abatacept 2 mg/kg
on days 1, 15 and 30 and every 30 days thereafter (105)
10–30 mg per week of MTX+abatacept 10 mg/kg
on days 1, 15 and 30 and every 30 days (115)
48
Genovese et al,
2005
26
393 (391) 322 Active RA despite at least
3 months of TNF-a blocker
DMARDs+placebo (133)
DMARDs+10 mg/kg of abatacept on
days 1, 15, 29 and every 28 days (258)
24
Kremer et al,
2006
27
656 (652) 547 Active RA despite MTX >15 mg per week of MTX+placebo (219)
>15 mg per week of MTX+10 mg/kg of abatacept
on days 1, 15 and 29, and every 28 days (433)
48
Weinblatt et al,
2006
28
1456 (1441) 1231 Active RA despite biological
or non-biological DMARDs
At least 1 non-biological DMARD+placebo (418)
1 biological DMARD+placebo (64)
At least 1 non-biological DMARD+10 mg/kg of
abatacept on days 1, 15 and 29 and every
4 weeks thereafter for a total of 14
infusions (856)
1 biological DMARD+10 mg/kg of abatacept
on days 1, 15 and 29 and every 4 weeks
thereafter for a total of
14 infusions (103)
48
Anakinra
Bresnihan et al,
1998
8
472 (472) 468 Active and severe RA Placebo (121)
30 mg daily of anakinra (119)
75 mg daily of anakinra (116)
150 mg daily of anakinra (116)
24
Cohen et al,
2002
29
419 (419) 331 Moderate to severe active
RA despite MTX
MTX (15–25 mg/wk)+placebo (74)
MTX (15–25 mg/wk)+daily 0.04 or 0.01 or 0.4
or 1 or 2 mg/kg of anakinra (345)
24
Cohen et al,
2004
30
506 (501) 492 Active RA despite MTX MTX (10–25 mg/wk)+placebo (251)
MTX (10–25 mg/wk)+100 mg per day
of anakinra (250)
24
Schiff et al,
2004{
31
1414 (1399) 1105 Active RA with and without
comorbidity factor
DMARDS+placebo (283)
DMARD+100 mg per day of anakinra (1116)
24
RA, rheumatoid arthritis; MTX, methotrexate; DMARDs, disease-modifying antirheumatic drugs; wk, week.
*Number of patients who received at least one dose of study medication in this arm of randomisation and were analysed.
{Including 951 patients with comorbidity factors (775 in the anakinra group and 196 in the placebo group).
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when high-dose group of anakinra was compared with placebo
and low-dose groups, the risk of serious infections was increased
during anakinra treatment with ORs of 3.40 (95% CI, 1.11 to
10.46) and 9.63 (95% CI, 1.31 to 70.91) respectively. For high
doses of rituximab and abatacept, we observed a tendency
towards an increased risk during biological agent treatments
versus low-dose groups: ORs were 7.20 (95% CI, 0.43 to 120.66)
and 2.16 (95% CI, 0.52 to 8.98) respectively. Thus, although CIs
include 1, there is a lingering concern for infectious risks with
these drugs. The serious infections reported were in the
majority bacterial and bronchopulmonary. Opportunistic infec-
tions seemed to be unusual. Indeed only two were described
during abatacept treatment: one case of tuberculosis (uncon-
firmed) and one of pulmonary aspergillosis.
Randomised controlled trials are often not adapted to
demonstrate an increased risk for rare side-effects because the
numbers of patients analysed are too small and the exposure
time too brief. Post-approval observational studies usually lack a
control group, which means establishing causality between a
treatment and an event is impossible. Therefore, to pool results
of randomised controlled trials by meta-analysis, is an interest-
ing and powerful alternative.
17 19
Incidences of serious infections observed in the trials analysed
are close to other published incidences in RA. Among the 2112
patients receiving placebo, 28 had a serious infection. The
Table 2 Summary of serious infections* in the 12 randomised placebo-controlled trials included in these
meta-analyses
Treatment
No. of trials
(references)
No. of patients
treated{ (biological/
placebo groups)
Duration of
follow-up
(weeks)
No. of patients with
at least 1 serious
infection in
biotherapy groups
and by dose group
(no. of participants)
No. of patients
with at least 1
serious infection
in placebo groups
(no. of participants)
Rituximab 3
10 22 23 1143 (745/398) 24–48 0 Rituximab
500 mg (124)
6 (398)
17 Rituximab 1000 mg (621)
Abatacept 5
9 24–28 2945 (1960/985) 24–48 0 Abatacept 0.5 mg/kg (26) 18 (985)
2 Abatacept 2 mg/kg (137)
47 Abatacept 10 mg/kg (1797)
Anakinra 4
8 29–31 2771 (2062/729) 24 0 Anakinra 0.04 mg/kg (63) 4 (729)
0 Anakinra 0.1 mg/kg (74)
0 Anakinra 0.4 mg/kg (77)
0 Anakinra 1 mg/kg (59)
0 Anakinra 2 mg/kg (72)
0 Anakinra 30 mg per day (119)
1 Anakinra 75 mg per day (116)
25 Anakinra 100 mg per day (1367)
4 Anakinra 150 mg per day (116)
*Serious infection was defined as life-threatening, requiring intravenous antibiotics or hospitalisation.
{Number of patients who received at least one dose of study medication in this arm of randomisation and were analysed.
Table 3 Risk of serious infections in patients with RA during rituximab, abatacept and anakinra treatments in
randomised placebo-controlled trials
Source Treatment
No. of patients with
at least 1 serious
infection/total in
treatment groups
(incidence %)
No. of patients with
at least 1 serious
infection/total in
placebo groups
(incidence %) Pooled ORs* (95% CI)
Edwards et al, 2004 Rituximab 6/121 (4.9) 1/40 (2.5) 1.45 (0.56 to 3.73)
Emery et al, 2006 4/316 (1.2) 2/149 (1.3)
Cohen et al, 2006 7/308 (2.3) 3/209 (1.4)
Total 17/745 (2.3) 6/398 (1.5)
Moreland et al, 2002 Abatacept 1/90 (1.11) 0/32 (0) 1.35 (0.78 to 2.32)
Kremer et al, 2005 1/220 (0.45) 2/119 (1.7)
Genovese et al, 2005 6/258 (2.3) 3/133 (2.2)
Kremer et al, 2006 13/433 (3.0) 5/219 (2.3)
Weinblatt et al, 2006 28/959 (2.9) 8/482 (1.6)
Total 49/1960 (2.5) 18/985 (1.8)
Bresnihan et al, 1998 Anakinra 5/351 (1.42) 1/121 (0.82) 2.75 (0.90 to 8.35)
Cohen et al, 2002 0/345 (0) 0/74 (0)
Cohen et al, 2004 2/250 (0.80) 2/251 (0.8)
Schiff et al, 2004 23/1116 (2.0) 1/283 (0.3)
Total 30/2062 (1.4) 4/729 (0.5)
*Using the Mantel–Haenszel method to calculate a pooled ORs with fixed effect.
x
2 (test OR differs from 1): for Rituximab: x
2=0.29, p=0.6, for Abatacept: x
2=0.94, p=0.3, for Anakinra: x
2=2.5, p=0.1.
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groups of other controlled trials in patients with RA. Indeed, in
the nine randomised controlled trials that evaluated anti-TNF
antibodies, 26 serious infections were reported among 1512
patients receiving placebo (incidence 1.7%).
17 High-dose ana-
kinra (>100 mg) seemed to increase the risk of serious
infections. This result concerned 1399 treated patients of whom
755 participants had at least one comorbid condition (such as
cardiovascular, pulmonary, diabetes, a history of infection, renal
impairment, etc.).
31–33 Indeed, when we excluded from the meta-
analysis the patients with comorbidity, the OR no longer
showed a significantly increased risk in the high-dose anakinra
group. Thus comorbidity factors appear to play a part in these
results. The long-term safety of anakinra treatment was
evaluated in an open-label study following the randomised
phase. A total of 1346 patients received anakinra for up to
3 years.
34 Serious infections were defined as infections necessi-
tating hospitalisation or the use of intravenous antibiotics. The
incidence rates (per 100 patient-years) of serious infections
concerning patients receiving anakinra were 5.2 during the first
placebo-controlled 6 months (versus 1.6 for placebo group) and
5.4 over the 36 months. The most frequent infections were
pneumonia and cellulitis. Thus long-term use of anakinra
appears to be safe in patients with RA. Nevertheless, this study
showed that patients who received steroids as concomitant
treatment at baseline were much more likely to experience a
serious infection (7.13 per 100 patient-years in patients with
steroids versus 2.87 per 100 patient-years for patients without).
In this meta-analysis, we could not evaluate the interaction
between corticosteroid and anakinra because individual data
were not available, the present study cannot fully clarify the
issue of an interaction between steroids and anakinra or the role
of individual comorbidity factors.
This systematic review was performed using all available
literature sources and includes all data published to date.
Furthermore, the meta-analysis conforms to the recommenda-
tions of the Cochrane collaboration. Therefore we consider
these results to be valid. However, this study does have
shortcomings. Only published data were analysed, thus we
cannot exclude the possibility of publication bias. If the reasons
that studies remain unpublished are associated with their
outcome, then the results of a meta-analysis could be biased.
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Furthermore, biases in patient selection may influence the final
results, ie the exclusion from the trials of patients with
comorbidities and previous serious infections. However, in four
trials evaluating rituximab or abatacept, some patients had
received previously one TNF-a blocker. In Genovese’s trial, all
patients (391) were previously treated with one TNF-a
blocker.
25 These data lacked in Moreland et al’s trial.
9
Concerning rituximab, 769 patients (of the 1143) received
previously a TNF blocker.
22 23 It is possible that these patients
were not at high risk of serious infection (we suppose that
patients previously treated with TNF blockers were screened
twice and that those who had a serious infection during the
Figure 2 Effect of biological agents (rituxumab, abatacept and
anakinra) versus placebo on serious infections (Forest plot).
Table 4 Risk of serious infections stratified by high- and low-dose dose
groups
Treatment
ORs (95% CIs)
High-dose* versus
placebo groups
Low-dose{ versus
placebo groups
High-dose* versus
low-dose{ groups
Rituximab 1.68
(0.64 to 4.35)
0.24
(0.01 to 4.33)
7.20
(0.43 to 120.66)
Abatacept 1.35
(0.78 to 2.33)
0.84
(0.13 to 5.30)
2.16
(0.52 to 8.98)
1.24
(0.70 to 2.29){
2.0
(0.48 to 8.33){
Anakinra 3.40
(1.11 to 10.46)
0.51
(0.03 to 8.27)
9.63
(1.31 to 70.91)
1.67
(0.51 to 5.41)1
6.41
(0.81 to 50.30)1
*High-dose groups were defined as 1000 mg for rituximab, 10 mg/kg for abatacept
and >100 mg for anakinra.
{Low-dose groups were defined as 500 mg for rituximab, (2 mg/kg for abatacept
and ,100 mg for anakinra.
{Calculated ORs when patients receiving biological DMARD as concomitant treatment
were excluded.
1Calculated ORs when patients with comorbidity factors were excluded.
Extended report
30 Ann Rheum Dis 2009;68:25–32. doi:10.1136/ard.2007.083188TNF blocker treatment were not included in another trial
evaluating a biological agent).
These meta-analyses do not demonstrate an increased risk of
serious infections with the biological agents analysed. One of
the important issues with these results is the potential lack of
power. Thus, for each biological agent we calculated a posteriori
the number of patients that it would be necessary to analyse in
treated and placebo groups to demonstrate the increase in risk
that was observed, though it was non-significant, with a power
of 80% (a risk=5%). In each group, for rituximab, 4569
patients would be necessary, and 6737 for abatacept. Thus,
these meta-analyses are underpowered to detect the observed
magnitude of difference in infection risk for these two biological
agents. However, for anakinra, the number of patients
necessary was 1820 in each group. This meta-analysis included
a sufficient number of patients in the anakinra arm (2062) but
only 729 patients in the placebo group, thus lack of power is less
an issue for anakinra. Because of this lack of power, it is not
possible to ascertain completely the absence of infectious risks
due to the analysed biological agents.
Like TNF-a blockers, anakinra is an anticytokine biological
agent. TNF-a blockers increase the risk of opportunistic
infections in patients with RA, most frequently due to
intracellular organisms. Tuberculosis, especially extrapulmon-
ary and disseminated, was the most frequently reported
granulomatous infection and occurred with the three TNF-a
blockers.
34–36 Invasive opportunistic infections occurring with
the three TNF-a blockers have been reported, such as listeriosis,
candidosis, histoplasmosis, nocardiosis, aspergillosis, pneumo-
cystosis, etc.
39–41 In the present meta-analysis, tuberculosis and
opportunistic infections seem to be exceptional during ritux-
imab, abatacept or anakinra treatments, thus demonstrating the
difference in mechanisms of action between these biotherapies,
especially against intracellular organisms.
According to these meta-analyses performed on the basis of
randomised placebo-controlled trials, rituximab, abatacept and
anakinra seem to be safe as regards the risk of serious infections.
Nevertheless, an increased risk was observed for high doses of
anakinra (>100 mg) in patients with comorbidity factors.
Moreover, such clinical trials select patients who are not
representative of all patients with RA in daily practice. Thus
the use of these biological agents will require careful monitoring
in daily practice especially in patients with comorbidity
conditions and with concomitant treatments, such as steroids.
Further, large-scale, post-marketing studies will have to confirm
these data.
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